AMERICAN ACADEMIC PUBLISHER

INTERNATIONAL JOURNAL OF MEDICAL SCIENCES

ISSN NUMBER: 2692 - 5206 Volume 6. No 02. February ,2026

SPECIFIC FEATURES OF ANESTHESIA IN PATIENTS WITH LIVER FAILURE

Khakhorova Marjona Farkhodovna

Department of Fundamental Medical Sciences of the

Asia International University. Bukhara, Uzbekistan.

Abstract: Liver failure represents a complex clinical condition characterized by profound metabolic, hemodynamic, and hematological disturbances that significantly influence perioperative management. Because the liver is central to drug metabolism, protein synthesis, coagulation regulation, immune modulation, and maintenance of systemic homeostasis, hepatic dysfunction creates substantial challenges for anesthesiologists. Altered pharmacokinetics and pharmacodynamics, reduced hepatic blood flow, portal hypertension, ascites, renal dysfunction, and susceptibility to encephalopathy increase perioperative morbidity and mortality. The selection and titration of anesthetic agents require careful consideration of reduced metabolic capacity and altered protein binding. Furthermore, perioperative stress may precipitate hepatic decompensation in vulnerable patients. This article provides a comprehensive and clinically oriented review of pathophysiological alterations in liver failure and discusses evidence-based strategies for preoperative risk stratification, intraoperative anesthetic management, coagulation correction, fluid therapy, and postoperative monitoring. An individualized, multidisciplinary, and physiology-driven approach is essential to optimize outcomes in this high-risk population.

Keywords: liver failure, anesthesia management, cirrhosis, perioperative risk, pharmacokinetics, hepatic dysfunction, coagulopathy

Introduction

Liver failure may present as acute liver failure, acute-on-chronic liver failure, or end-stage chronic liver disease. Chronic liver disease, most commonly resulting from viral hepatitis, alcohol-related liver injury, or nonalcoholic fatty liver disease, is a major global health burden. Progressive fibrosis and cirrhosis lead to architectural distortion of hepatic parenchyma, portal hypertension, and impaired synthetic and metabolic function. From an anesthetic standpoint, these structural and functional changes profoundly modify the body's response to surgical stress and anesthetic drugs.

Perioperative mortality correlates strongly with the severity of liver dysfunction. Even minor surgical procedures may trigger hepatic decompensation in advanced cirrhosis. Therefore, anesthetic management in such patients is not merely technical but requires deep understanding of hepatic physiology, careful drug selection, and continuous hemodynamic optimization.

Systemic Pathophysiological Alterations

In liver failure, hepatocellular dysfunction reduces the activity of phase I and phase II metabolic pathways. Cytochrome P450 enzyme activity declines, impairing oxidative metabolism of many anesthetic agents. Drugs with high hepatic extraction ratios become highly dependent on hepatic blood flow, whereas drugs with low extraction ratios depend more on intrinsic enzymatic capacity. Both mechanisms are compromised in advanced disease.

Hypoalbuminemia is a hallmark of chronic liver failure. Because many anesthetic agents are protein-bound, reduced albumin increases the pharmacologically active free fraction of drugs,

AMERICAN ACADEMIC PUBLISHER
INTERNATIONAL JOURNAL OF MEDICAL SCIENCES
ISSN NUMBER: 2692 - 5206 Volume 6. No 02. February ,2026

potentially enhancing both desired and adverse effects. In addition, increased volume of distribution in ascitic patients alters drug kinetics.

Hemostatic abnormalities are complex. Although conventional laboratory tests suggest a bleeding tendency, the hemostatic system is often rebalanced but fragile. Patients remain at risk for both hemorrhage and thrombosis. This delicate equilibrium must be considered before invasive procedures.

Cardiovascular changes include hyperdynamic circulation characterized by high cardiac output and low systemic vascular resistance. Splanchnic vasodilation reduces effective arterial blood volume, activating neurohormonal compensatory mechanisms that predispose patients to renal dysfunction. These factors make intraoperative hypotension particularly dangerous.

Preoperative Risk Stratification and Optimization

Assessment begins with detailed history and physical examination, focusing on prior episodes of decompensation such as ascites, variceal bleeding, or encephalopathy. Objective scoring systems including the Child–Pugh classification and MELD score provide standardized evaluation of severity and predict perioperative mortality.

Laboratory testing should evaluate bilirubin, transaminases, albumin, prothrombin time, INR, platelet count, creatinine, and serum electrolytes. Renal dysfunction significantly worsens prognosis and must be carefully assessed.

Preoperative optimization may include diuretic adjustment, therapeutic paracentesis for tense ascites, correction of electrolyte imbalance, nutritional supplementation, and treatment of encephalopathy with lactulose or rifaximin where indicated. Elective surgery should be deferred in patients with active acute hepatitis or severe decompensation.

Principles of Intraoperative Anesthetic Management

The primary intraoperative objective is preservation of hepatic perfusion and avoidance of secondary insults such as hypoxia, hypotension, hypercapnia, and excessive blood loss. Induction agents must be titrated slowly. Reduced doses are often sufficient due to increased sensitivity.

Propofol remains widely used because of rapid redistribution and relatively predictable recovery profile. Etomidate may be advantageous in patients with limited cardiovascular reserve. Long-acting benzodiazepines should generally be avoided due to risk of prolonged sedation and postoperative encephalopathy.

Short-acting opioids are preferable. Remifentanil, metabolized by plasma esterases, offers predictable offset independent of hepatic function. Neuromuscular blockers undergoing Hofmann elimination provide additional safety in severe dysfunction.

Inhalational anesthetics with minimal hepatic metabolism are acceptable, provided hemodynamic stability is maintained. Close arterial pressure monitoring and, in high-risk cases, invasive hemodynamic monitoring may be justified.

AMERICAN ACADEMIC PUBLISHER
INTERNATIONAL JOURNAL OF MEDICAL SCIENCES
ISSN NUMBER: 2692 - 5206 Volume 6. No 02. February ,2026

Fluid Therapy and Hemodynamic Control

Fluid therapy must balance the competing risks of hypoperfusion and fluid overload. Excess crystalloid administration may exacerbate ascites and tissue edema, whereas inadequate resuscitation compromises hepatic and renal perfusion.

Balanced electrolyte solutions are generally preferred over chloride-rich fluids. Albumin administration may be considered in selected patients to improve oncotic pressure and circulatory stability. Vasopressors such as norepinephrine are often required to counteract vasodilation and maintain mean arterial pressure.

Postoperative Management and Complications

The postoperative period is critical, as surgical stress may precipitate acute-on-chronic liver failure. Monitoring should include serial assessment of liver function tests, coagulation profile, renal parameters, and mental status.

Early identification of hepatic encephalopathy is essential. Sedatives should be minimized, and analgesic regimens must avoid hepatotoxic drugs. Multimodal analgesia with dose adjustment is recommended.

Infections occur more frequently in cirrhotic patients due to immune dysfunction. Strict aseptic technique and early treatment of suspected infection are mandatory.

Conclusion

Anesthesia in patients with liver failure requires comprehensive understanding of altered physiology and individualized clinical judgment. Successful management depends on meticulous preoperative evaluation, rational pharmacological selection, preservation of hepatic perfusion, cautious fluid therapy, and vigilant postoperative surveillance. A multidisciplinary strategy integrating anesthesiology, surgery, hepatology, and intensive care expertise significantly improves perioperative safety. Future research should continue to refine pharmacological protocols and develop predictive models that enhance individualized perioperative planning.

References

1. Butterworth JF, Mackey DC, Wasnick JD. Morgan & Mikhail's Clinical Anesthesiology. 6th ed. McGraw-Hill; 2018.

2. Miller RD, Cohen NH, Eriksson LI, et al. Miller's Anesthesia. 9th ed. Elsevier; 2020.

3. Friedman LS. The risk of surgery in patients with liver disease. Clin Liver Dis. 2019.

4. O'Leary JG, et al. AGA clinical practice update on surgical risk assessment in cirrhosis. Gastroenterology. 2019.

5. Northup PG, et al. MELD score and perioperative mortality. Hepatology. 2005.

6. Rahman S, et al. Drug metabolism in hepatic impairment. Clin Pharmacokinet. 2020.

7. Nguyen N, et al. Perioperative management of advanced liver disease. Anesth Clin. 2021.

8. Jalan R, et al. Acute-on-chronic liver failure: pathophysiology and management. J Hepatol. 2021.